Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances

Trial Profile

Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2018 Primary endpoint (1-year Survial rate of good-risk patients) has been met, according to results published in the European Journal of Cancer.
    • 14 Mar 2018 Results (n=150) assessing the efficacy of gemcitabine plus erlotinib (gem/erlotinib) in rash-positive patients, were published in the European Journal of Cancer.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top